Dihexa Research: What the Published Studies Investigated — and Their Current Status
Dihexa research is the study of a small angiotensin-IV-derived peptidomimetic (development code PNB-0408). This page summarises what the literature investigated, cited neutrally and framed as “studies investigated.” The honest, defining point up front: the evidence base is entirely preclinical (cell culture and rodent), it is small, its two core primary papers now carry post-publication integrity notices, and there is no human clinical data on Dihexa itself.
What is Dihexa?
What is Dihexa? It is a small, reportedly orally active and blood-brain-barrier-permeant oligopeptide, or peptidomimetic, derived from angiotensin IV (AngIV). It carries the development code PNB-0408 (CAS 1401708-83-5), and its chemical name is N-hexanoic-Tyr-Ile-(6)aminohexanoic amide. It was developed by the Wright and Harding group at Washington State University and later advanced commercially (M3 Biotechnology). That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people. As stated above, no human clinical data exist for Dihexa itself, and its foundational mechanism literature is now flagged.
Molecule properties
Dihexa is a small peptidomimetic built on a Tyr-Ile core capped with a hexanoic-acid group at one end and a 6-aminohexanoic-amide group at the other. Those caps were engineered from the parent AngIV peptide with a specific design rationale: to increase metabolic stability and lipophilicity, so that the modifications would resist peptidase cleavage relative to the native peptide. In research catalogues it is supplied as a lyophilized powder for laboratory use. These are molecule-identity and design facts only — this page gives no reconstitution, handling, or administration content, and none of the structural rationale should be read as a claim about activity in a person.
The mechanism researchers proposed
The proposed Dihexa mechanism is reported here strictly as what studies investigated, and each claim is tied to a source whose current status is stated. Read the whole section with that caveat in place:
- HGF / c-Met potentiation — Benoist et al. (2014, J Pharmacol Exp Ther) reported that Dihexa binds hepatocyte growth factor (HGF) with high affinity and acts as an allosteric potentiator, enhancing HGF-driven phosphorylation of the c-Met receptor at otherwise subthreshold HGF concentrations. Stated immediately for accuracy: this paper was retracted in 2025 (see the models and status section below).
- Hippocampal spinogenesis / synaptogenesis — the same line of work described increased dendritic spine density and synapse formation in hippocampal neuron cultures, reportedly dependent on the HGF/c-Met system, as the effect was said to be blocked by an HGF antagonist and by c-Met knockdown.
- Downstream signalling — PI3K/AKT-associated pathways downstream of c-Met were described as the proposed route to the observed spine changes in those culture models.
Because the primary mechanism papers now carry integrity notices, every statement above should be read as proposed and contested, not established. Each bullet names a pathway a study examined in cells, not an effect a reader would experience. This page does not repeat the potency-superlative language that appears in vendor write-ups; that framing originates in the flagged papers and is not treated here as fact.
Research models — and the honest limits
The models in the Dihexa literature are preclinical only. On the cell side, cultured hippocampal neurons were used for the spine and synapse assays. On the animal side, rodent behavioural tasks — including aged-rat and scopolamine-impairment spatial-learning paradigms — were described in McCoy et al. (2013, J Pharmacol Exp Ther). To be plain, and to repeat the point deliberately: there is no interventional human data on Dihexa; the entire body of evidence is cell-culture and rodent, and preclinical findings cannot establish human outcomes.
Post-publication status (stated neutrally, because a researcher needs it): McCoy et al. (2013) carries a Notice of Concern (2021). Benoist et al. (2014) carries a 2021 Expression of Concern and was formally retracted in 2025 following a research-integrity review at the originating institution. These facts are reported as a matter of public record, without speculation about motives or individuals.
A related but distinct clinical compound (context, not endorsement): a structurally related, separately developed prodrug called fosgonimeton (ATH-1017) was tested in humans by Athira Pharma; its Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024) did not meet its primary endpoints. Fosgonimeton is a different molecule, and this outcome says nothing about Dihexa itself — it neither validates nor refutes the Dihexa literature, and it does not imply any human use of Dihexa.
Dihexa among angiotensin-IV-derived research peptides
In one line: Dihexa sits within the broader AngIV / HGF-c-Met research line, where the shared research question is whether AngIV-derived molecules engage that growth-factor system. That is a family-and-target framing, not a ranking and not use advice. What places Dihexa in this area — its AngIV lineage and the proposed HGF/c-Met target — is also why interpretation is currently cautious: the core primary papers are flagged, so the position is best read as “an early, contested entry in a target-based research line.” For neighbouring neuro/cognition research explainers handled on their own terms, see Cerebrolysin research and Semax research. This page hands off rather than merging distinct literatures.
Research-grade sourcing and verification
For laboratory research use only, Dihexa is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, with lot-level verification. Confirming catalogue identity matters especially for a small, novel peptidomimetic like this one. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and identity/purity framing only — no outcome framing.
Verify a batch
Every order ships with a per-batch Certificate of Analysis. Have a vial in hand? Enter its lot number to look up the COA for that exact batch.
Frequently asked questions
What is Dihexa derived from?
What mechanism did studies propose for Dihexa?
Has Dihexa been studied in humans?
Have any Dihexa studies been retracted?
What is fosgonimeton and how is it related?
Literature cited
- McCoy AT, Benoist CC, Wright JW, et al. “Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents.” J Pharmacol Exp Ther. 2013;344(1):141–154. PMID 23055539. (Characterization; oral activity, BBB permeability, rodent spatial-learning models. Carries a 2021 Notice of Concern — PMID 34551989.)
- Benoist CC, Kawas LH, Zhu M, et al. “The Procognitive and Synaptogenic Effects of Angiotensin IV–Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System.” J Pharmacol Exp Ther. 2014;351(2):390–402. PMID 25187433; PMC4201273. Retracted 2025 (J Pharmacol Exp Ther 2025;392(4):103567); Expression of Concern 2021.
- Wright JW, Harding JW. “The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer’s Disease.” J Alzheimers Dis. 2015;45(4):985–1000. PMID 25649658. (Review context authored by the originating group; background framing only.)
- Clinical-context (distinct compound): Athira Pharma LIFT-AD Phase 2/3 trial of fosgonimeton (ATH-1017), ClinicalTrials.gov NCT04488419; topline reported 2024 as not meeting primary/key secondary endpoints. (Fosgonimeton is a separate prodrug, not Dihexa.)
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. All products are sold strictly for in-vitro laboratory research and are not intended for human or veterinary use, ingestion, or administration. Nothing on this page is a medical or efficacy claim. You must be 21 or older to browse this catalog.